United BioSource Acquires Abt Bio-Pharma Solutions
United BioSource Corporation (UBC)
announced the acquisition of
Abt Bio-Pharma Solutions, Inc.
(ABS), a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries.
The acquisition of ABS is part of UBC’s ongoing strategy to build a “best in class” portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies. With this acquisition UBC further expands its team of senior experts in comparative effectiveness and comparative value; increases its registry and observational study practices; and reinforces its commercial strategy and market access capabilities.
“UBC is an ideal home for ABS,” said Abt Associates Chief Executive Officer Kathleen Flanagan. “We are gratified to see our colleagues join an organization that shares our values. At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support the development and commercialization of their products.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
